BioToxTech Co

BioToxTech Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 378.75 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 147.83 % — a change of 156.21% (higher).

FCF Conversion

378.75 %

YoY

156.21%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of BioToxTech Co is 2025 378.75 % . FCF Conversion Rate (FCF/EBITDA) of BioToxTech Co was 2024 147.83 % . It decreases by 156.21% higher compared to the previous year.

The BioToxTech Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
20.49 KRW
Jan 1, 2019
-62.87 KRW
Jan 1, 2020
122.33 KRW
Jan 1, 2021
-46.00 KRW
Jan 1, 2022
-1,177.69 KRW
Jan 1, 2023
433.02 KRW
Jan 1, 2024
147.83 KRW
Jan 1, 2025
378.75 KRW
The BioToxTech Co FCF Conversion history
YEARFCF ConversionYoY
378.75 %+156.21%
147.83 %-65.86%
433.02 %-136.77%
-1,177.69 %+2,460.13%
-46.00 %-137.60%
122.33 %-294.58%
-62.87 %-406.81%
20.49 %-89.09%
187.87 %-59.04%
458.64 %+1,283.58%
33.15 %-36.14%
51.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

FCF Conversion Rate (FCF/EBITDA) of BioToxTech Co is 378.75 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of BioToxTech Co changed from 147.83 % to 378.75 %, representing a 156.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioToxTech Co

All Key Metrics — BioToxTech Co